Evidence map›Paper›PMID 40865632›Full record

ReviewJournal of advanced research2026

GLP-1 and GIP: Magic bullet for musculoskeletal diseases?

Qihang Fang, Gan Li, Pei Liu, Peng Ding, Youshui Gao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qihang FangDepartment of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China; Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
Gan LiDepartment of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China; Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
Pei LiuDepartment of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China; Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
Peng DingDepartment of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China; Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China. Electronic address: dingpeng0902@gmail.com.
Youshui GaoDepartment of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China; Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China. Electronic address: gaoyoushui@sjtu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMusculoskeletal diseases (MSDs) are prevalent health problems that have a chronic course and are closely related to metabolic disorders. Several incretins, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), which are secreted by enteroendocrine cells in response to food intake. In animal experiments, more and more evidence showed that there's a potential connection between GLP-1/GIP and musculoskeletal system cells (such as mesenchymal stem cells, osteoblasts and osteoclasts). As the GLP-1/GIP analogs have obtained global application as slimming magic bullet, it is of interest to further explore whether they are also magic bullet for MSDs apart from merely focusing on its weight-losing effect. AIM OF REVIEW: To help figure out whether GLP-1/GIP is beneficial for musculoskeletal system, this review summarizes the effects of GLP-1 and GIP on musculoskeletal cells and their probable mechanisms. Current results concerning the effects of GLP-1 and GIP in rodent experiments and clinical studies related to the musculoskeletal system are also summarized. Future research should prioritize confirming experimental results through clinical trials, address previous research gaps, and focus on the long-term impact of GLP-1 and GIP. KEY SCIENTIFIC CONCEPTS OF REVIEW: GLP-1 and GIP may exert protective effect on musculoskeletal cells through multiple pathways besides weight management and glucose control. Further clinical studies are needed to verify these findings. As the GLP-1/GIP analog going viral, it is of huge significance to explore the clinical value of this drug in treating MSDs.

Indexed as

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1Musculoskeletal DiseasesAnimalsHumansIncretinsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsClinical trialGIPGLP-1MechanismMusculoskeletal system

Identifiers

PMID40865632
PMCPMC13131528

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.